A Phase 2 interventional study of Galunisertib and Lomustine in Glioblastoma, sponsored by Eli Lilly and Company. Completed at 29 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing lomustine in Glioblastoma — 3 open to participants now, 4 under way, 2 of them phase 3. Lomustine · Glioblastoma.
Among the 22 studies testing lomustine in Glioblastoma, this one is the 5th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 2, and was the 9th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →3 of the 22 studies testing lomustine in Glioblastoma are open now, in 5 countries. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages 18+
Vastra Gotaland Region · Sites in Austria, Denmark, Norway and 1 more country
Ages 18–70
The University of Texas Health Science Center at San Antonio · Sites in United States
By country, each count listing its studies:
Lomustine: first FDA approval 1976 (GLEOSTINE). What it is approved for, and how studies give it, is on its page →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 5
First in 2002; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 68 across the 22 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 22 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 8 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing lomustine in Glioblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07145112University of California, DavisLaser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing lomustine in Glioblastoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Participants received Galunisertib 300 milligrams (mg) orally twice daily (BID) for 14 days, followed by 14 days of rest in a 28-day cycle. * Treatment continued until disease progression, death, or discontinuation criteria were met.
Drug: Galunisertib
* Participants received Galunisertib 300 mg orally BID for 14 days, followed by 14 days of rest in a 28-day cycle. * Participants received a first dose of Lomustine at 100 milligrams per square meter (mg/m²) administered orally. Thereafter, starting with the second dose, Lomustine was administered orally once every 6 weeks at 100-130 mg/m², at the discretion of the investigator. * Treatment continued until disease progression, death, or discontinuation criteria were met.
Drug: Galunisertib · Drug: Lomustine
* Participants received a first dose of Lomustine at 100 mg/m² administered orally. Thereafter, starting with the second dose, Lomustine was administered orally once every 6 weeks at 100-130 mg/m², at the discretion of the investigator. * Participants received Galunisertib-matched Placebo orally BID for 14 days, followed by 14 days of rest in a 28-day cycle. * Treatment continued until disease progression, death, or discontinuation criteria were met.
Drug: Lomustine · Drug: Placebo
Administered orally
Also known as: LY2157299 monohydrate
Administered orally
Administered orally
Also known as: Galunisertib-matched Placebo
Overall Survival (OS)
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive.
Time frame: Randomization to Date of Death from Any Cause (Up To 20.5 Months)
Progression Free Survival (PFS)
PFS was defined as the time from randomization to the date of the first observation of objective disease progression or death from any cause, whichever occurred first. Participants known to be alive and without disease progression were censored at the date of their last objective progression-free disease assessment prior to the initiation of any subsequent systemic anticancer therapy.
Time frame: Randomization to Objective Progression or Death Due to Any Cause (Up To 19 Months)
Percentage of Participants With Tumour Response
Tumour response was assessed using Response Assessment in Neuro-Oncology (RANO) criteria. Responses included Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD). CR required disappearance of all enhancing lesions, no new lesions, stable or improved non-enhancing lesions, and no corticosteroid use. PR was defined as ≥50% reduction in enhancing lesion size, no new lesions, stable or improved non-enhancing lesions, and stable or reduced corticosteroid use. SD indicated no significant change in lesion size or clinical status. PD was defined as ≥25% increase in lesion size, new lesions, or clinical deterioration. Percentage of participants with tumor response is defined as the percentage of participants who achieved these tumor responses based on RANO criteria.Participants whose tumor response could not be assessed due to inadequate imaging data were categorized as 'Unknown'.
Time frame: Randomization until measured progressive disease (Up To 19 Months)
Population Pharmacokinetics (PopPK): Absorption Rate Constant of Galunisertib (Arm A: Galunisertib and Arm B: Galunisertib + Lomustine)
The absorption rate constant (Ka) of Galunisertib was estimated using PopPK modeling based on plasma concentration-time data collected during Cycle 1. A two-compartment model with first-order absorption was applied using nonlinear mixed-effects modeling. Samples were collected at the following time points: Cycle 1 Day 1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose. Individual participant Ka values were derived from model-estimated parameters using all available PK timepoints.The reported outcome is the mean of these individual Ka estimates across both treatment arms (Arm A: Galunisertib; Arm B: Galunisertib + Lomustine).
Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose
Population Pharmacokinetics (PopPK): Mean Steady State Apparent Volume of Distribution (Vss) of Galunisertib (Arm A: Galunisertib and Arm B: Galunisertib + Lomustine)
The Vss at steady state of Galunisertib was estimated using PopPK modeling based on plasma concentration-time data collected during Cycle 1.A two-compartment model was applied using nonlinear mixed-effects modeling. Samples were collected at the following time points: Cycle 1 Day 1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose. Individual participant Vss values were derived from model-estimated parameters using all available PK timepoints. The reported outcome is the mean of individual Vss estimates across both treatment arms (Arm A: Galunisertib; Arm B: Galunisertib + Lomustine).
Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose
Population Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib (Arm A: Galunisertib and Arm B: Galunisertib + Lomustine)
The apparent clearance (CL/F) of Galunisertib was estimated using PopPK modeling based on plasma concentration-time data collected during Cycle 1. A two-compartment model was applied using nonlinear mixed-effects modeling. Samples were collected at the following time points: Cycle 1 Day 1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose. Individual participant CL/F values were derived from model-estimated parameters using all available PK timepoints. The reported outcome is the mean of these individual CL/F estimates across both treatment arms (Arm A: Galunisertib; Arm B: Galunisertib + Lomustine).
Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose
Change From Baseline in Neurocognitive Function Using Hopkins Verbal Learning Test-Revised (HVLT-R)
The Hopkins Verbal Learning Test-Revised comprises: * 3 Learning Trials: Participants were presented with a list of 12 words (from 3 semantic categories) and were asked to recall them to test verbal learning and memory. * Delayed Recall Trial: Conducted 20-25 minutes after the 3rd learning trial to test memory retention. * Delayed Recognition Trial: Participants identified previously presented words from a list that included 12 distractors to test recognition discrimination. Scoring Components: * Total Recall Score (0-36): Sum of correctly recalled words across the 3 learning trials. * Delayed Recall Score (0-12): Number of correct words recalled after the delay. * Recognition Discrimination Index Score (+12 to -12): Calculated as the number of true positives (correctly identified words) minus false positives (incorrectly identified words, i.e., distractors). For each of the 3 reported scores, higher scores = better neurocognitive performance; lower scores = decline.
Time frame: Baseline, Month 20
Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom and Interference Severity Scores: (Brain Tumor Symptoms, Core Symptoms, Interference Symptoms)
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It includes: * 13 core symptoms measuring severity of pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, memory problems, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness/tingling, rated 0-10, where 0 = "not present" and 10 = "as bad as you can imagine." * 9 brain tumor-specific symptoms assess severity of difficulty speaking, weakness, seizures, difficulty understanding, vision changes, appearance changes, bowel pattern changes, concentration problems, and irritability, rated 0-10, where 0 = "not present" and 10 = "as bad as you can imagine." * 6 interference items assess impact on general activity, mood, work, relations, walking, and enjoyment of life, rated 0-10, where 0 = "did not interfere" and 10 = "interfered completely."
Time frame: Baseline, Month 21
| Milestone | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo |
|---|---|---|---|
| Started | 39 | 79 | 40 |
| Received at least one dose of study drug | 39 | 79 | 40 |
| Safety analysis population | 40 | 78 | 40 |
| Completed | 38 | 79 | 40 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive.
| Months | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo |
|---|---|---|---|
| Overall Survival (OS) | 8.0 (NA to NA) | 6.7 (NA to NA) | 7.5 (NA to NA) |
PFS was defined as the time from randomization to the date of the first observation of objective disease progression or death from any cause, whichever occurred first. Participants known to be alive and without disease progression were censored at the date of their last objective progression-free disease assessment prior to the initiation of any subsequent systemic anticancer therapy.
| Months | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo |
|---|---|---|---|
| Progression Free Survival (PFS) | 1.8 (1.6 to 3.0) | 1.8 (1.7 to 1.8) | 1.9 (1.7 to 1.9) |
Tumour response was assessed using Response Assessment in Neuro-Oncology (RANO) criteria. Responses included Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD). CR required disappearance of all enhancing lesions, no new lesions, stable or improved non-enhancing lesions, and no corticosteroid use. PR was defined as ≥50% reduction in enhancing lesion size, no new lesions, stable or improved non-enhancing lesions, and stable or reduced corticosteroid use. SD indicated no significant change in lesion size or clinical status. PD was defined as ≥25% increase in lesion size, new lesions, or clinical deterioration. Percentage of participants with tumor response is defined as the percentage of participants who achieved these tumor responses based on RANO criteria.Participants whose tumor response could not be assessed due to inadequate imaging data were categorized as 'Unknown'.
| Percentage of participants | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo |
|---|---|---|---|
| CR | 0.0 | 1.3 | 0.0 |
| PR | 5.1 | 0.0 | 0.0 |
| SD | 25.6 | 20.3 | 30.0 |
| PD | 53.8 | 63.3 | 65.0 |
| Unknown | 15.4 | 15.2 | 5.0 |
The absorption rate constant (Ka) of Galunisertib was estimated using PopPK modeling based on plasma concentration-time data collected during Cycle 1. A two-compartment model with first-order absorption was applied using nonlinear mixed-effects modeling. Samples were collected at the following time points: Cycle 1 Day 1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose. Individual participant Ka values were derived from model-estimated parameters using all available PK timepoints.The reported outcome is the mean of these individual Ka estimates across both treatment arms (Arm A: Galunisertib; Arm B: Galunisertib + Lomustine).
| One per hour (1/hour) | Arm A: Galunisertib and Arm B: Galunisertib + Lomustine |
|---|---|
| Population Pharmacokinetics (PopPK): Absorption Rate Constant of Galunisertib (Arm A: Galunisertib and Arm B: Galunisertib + Lomustine) | 2.28 ± 26 |
The Vss at steady state of Galunisertib was estimated using PopPK modeling based on plasma concentration-time data collected during Cycle 1.A two-compartment model was applied using nonlinear mixed-effects modeling. Samples were collected at the following time points: Cycle 1 Day 1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose. Individual participant Vss values were derived from model-estimated parameters using all available PK timepoints. The reported outcome is the mean of individual Vss estimates across both treatment arms (Arm A: Galunisertib; Arm B: Galunisertib + Lomustine).
| Liters (L) | Arm A: Galunisertib and Arm B: Galunisertib + Lomustine |
|---|---|
| Population Pharmacokinetics (PopPK): Mean Steady State Apparent Volume of Distribution (Vss) of Galunisertib (Arm A: Galunisertib and Arm B: Galunisertib + Lomustine) | 175 ± 8.9 |
The apparent clearance (CL/F) of Galunisertib was estimated using PopPK modeling based on plasma concentration-time data collected during Cycle 1. A two-compartment model was applied using nonlinear mixed-effects modeling. Samples were collected at the following time points: Cycle 1 Day 1: Predose, 0.5-2 hours (h), 3.5-5 h, and 48 h post-dose; Day 14: Predose, 0.5-2 h, 3.5-5 h, 24 h, and 48 h post last dose. Individual participant CL/F values were derived from model-estimated parameters using all available PK timepoints. The reported outcome is the mean of these individual CL/F estimates across both treatment arms (Arm A: Galunisertib; Arm B: Galunisertib + Lomustine).
| Liter per hour (L/hr) | Arm A: Galunisertib and Arm B: Galunisertib + Lomustine |
|---|---|
| Population Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib (Arm A: Galunisertib and Arm B: Galunisertib + Lomustine) | 37.5 ± 5.0 |
The Hopkins Verbal Learning Test-Revised comprises: * 3 Learning Trials: Participants were presented with a list of 12 words (from 3 semantic categories) and were asked to recall them to test verbal learning and memory. * Delayed Recall Trial: Conducted 20-25 minutes after the 3rd learning trial to test memory retention. * Delayed Recognition Trial: Participants identified previously presented words from a list that included 12 distractors to test recognition discrimination. Scoring Components: * Total Recall Score (0-36): Sum of correctly recalled words across the 3 learning trials. * Delayed Recall Score (0-12): Number of correct words recalled after the delay. * Recognition Discrimination Index Score (+12 to -12): Calculated as the number of true positives (correctly identified words) minus false positives (incorrectly identified words, i.e., distractors). For each of the 3 reported scores, higher scores = better neurocognitive performance; lower scores = decline.
| Score on a scale | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo |
|---|---|---|---|
| Total Recall Score | -0.2 ± 1.4 | -0.2 ± 1.2 | -0.3 ± 1.5 |
| Delayed Recall Score | -0.8 ± 2.2 | 0.0 ± 1.4 | 0.1 ± 1.3 |
| Recognition Discrimination Index Score | -1.3 ± 5.1 | 0.7 ± 4.1 | 0.1 ± 2.0 |
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It includes: * 13 core symptoms measuring severity of pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, memory problems, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness/tingling, rated 0-10, where 0 = "not present" and 10 = "as bad as you can imagine." * 9 brain tumor-specific symptoms assess severity of difficulty speaking, weakness, seizures, difficulty understanding, vision changes, appearance changes, bowel pattern changes, concentration problems, and irritability, rated 0-10, where 0 = "not present" and 10 = "as bad as you can imagine." * 6 interference items assess impact on general activity, mood, work, relations, walking, and enjoyment of life, rated 0-10, where 0 = "did not interfere" and 10 = "interfered completely."
| Score on a scale | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo |
|---|---|---|---|
| Brain Tumor Symptoms | 0.0 ± 2.3 | 0.3 ± 1.9 | -0.3 ± 1.9 |
| Core Symptoms | 0.0 ± 1.5 | 0.3 ± 1.5 | 0.3 ± 0.9 |
| Interference Symptoms | 0.2 ± 2.8 | 0.8 ± 2.2 | 1.1 ± 3.0 |
Collected over Baseline Up to 11 years 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Galunisertib | 37/40 (92.5%) | 21/40 (52.5%) | 34/40 (85%) |
| Arm B: Galunisertib + Lomustine | 75/78 (96.2%) | 31/78 (39.7%) | 69/78 (88.5%) |
| Arm C: Lomustine + Placebo | 38/39 (97.4%) | 15/39 (38.5%) | 31/39 (79.5%) |
| Arm C: Lomustine + Placebo (Placebo Alone) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) |
| Event | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo | Arm C: Lomustine + Placebo (Placebo Alone) |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/40 | 0/78 | 0/39 | 1/1 |
| SeizureNervous system disorders | 7/40 | 4/78 | 1/39 | 0/1 |
| Brain oedemaNervous system disorders | 2/40 | 5/78 | 0/39 | 0/1 |
| General physical health deteriorationGeneral disorders | 0/40 | 0/78 | 2/39 | 0/1 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 | 1/78 | 2/39 | 0/1 |
| HemiparesisNervous system disorders | 2/40 | 4/78 | 1/39 | 0/1 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/40 | 0/78 | 0/39 | 0/1 |
| HeadacheNervous system disorders | 1/40 | 3/78 | 0/39 | 0/1 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/40 | 0/78 | 1/39 | 0/1 |
| FatigueGeneral disorders | 0/40 | 2/78 | 0/39 | 0/1 |
| Event | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo | Arm C: Lomustine + Placebo (Placebo Alone) |
|---|---|---|---|---|
| FatigueGeneral disorders | 10/40 | 20/78 | 14/39 | 0/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/40 | 21/78 | 12/39 | 0/1 |
| HeadacheNervous system disorders | 11/40 | 20/78 | 10/39 | 0/1 |
| NauseaGastrointestinal disorders | 6/40 | 13/78 | 8/39 | 0/1 |
| VomitingGastrointestinal disorders | 4/40 | 14/78 | 8/39 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 4/40 | 5/78 | 6/39 | 0/1 |
| HemiparesisNervous system disorders | 0/40 | 7/78 | 6/39 | 0/1 |
| AphasiaNervous system disorders | 6/40 | 4/78 | 3/39 | 0/1 |
| Weight increasedInvestigations | 1/40 | 3/78 | 5/39 | 0/1 |
| Confusional statePsychiatric disorders | 3/40 | 5/78 | 5/39 | 0/1 |
All randomized participants.
| Age, Continuous(years) | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo | Total |
|---|---|---|---|---|
| Mean | 56.6 ± 10.9 | 57.5 ± 9.3 | 56.9 ± 10.2 | 57.1 ± 9.9 |
| Sex: Female, Male(Participants) | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo | Total |
|---|---|---|---|---|
| Female | 18 | 21 | 17 | 56 |
| Male | 21 | 58 | 23 | 102 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 2 | 11 |
| Not Hispanic or Latino | 29 | 56 | 27 | 112 |
| Unknown or Not Reported | 7 | 17 | 11 | 35 |
| Race (NIH/OMB)(Participants) | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 30 | 60 | 29 | 119 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 16 | 10 | 33 |
| Region of Enrollment(Participants) | Arm A: Galunisertib | Arm B: Galunisertib + Lomustine | Arm C: Lomustine + Placebo | Total |
|---|---|---|---|---|
| Canada | 0 | 3 | 1 | 4 |
| Belgium | 3 | 8 | 3 | 14 |
| United States | 7 | 8 | 6 | 21 |
| Poland | 1 | 1 | 0 | 2 |
| Italy | 8 | 14 | 8 | 30 |
| Australia | 4 | 14 | 2 | 20 |
| France | 7 | 17 | 11 | 35 |
| Germany | 4 | 7 | 5 | 16 |
| Spain | 5 | 6 | 3 | 14 |
| Netherlands | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2012 to primary completion in Jul 2014, 27 months.
Results were first posted in Nov 2025, 11 years 3 months after primary completion. A results delay was requested in Sep 2014.
Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's 27 months is below that.
Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LY-2157299 · Lomustine